Pre-Qualify for Eversense 365
If you're on insulin, you might greatly benefit from Eversense 365, the implantable CGM that monitors glucose continuously for a year. Whether you’re ready to get started now or just have additional questions about Eversense, a Senseonics Diabetes Care representative can help.
You may pre-qualify for Eversense 365 based on your insurance type and diabetes therapy. Fill in and submit the form below and we’ll be in touch via phone or text. We’ll also send you information about Eversense 365 by email.
All fields marked with an asterisk (*) are required.
Thanks! We’ve got your info.
An Eversense Specialist will reach out within one business day to guide your next steps. The call may come from an unfamiliar number, so please keep an eye on your phone and voicemail.
If we can’t reach you, we'll follow up by text and email from an eversensecgm.com address (please check your spam folder just in case).
While you wait: Learn how the Eversense CGM works.
Good news! Eversense 365 may be a match.
Next, you'll connect with a live Eversense Specialist. They can answer important questions, including about insurance coverage. There are 2 ways to connect:
Call My Eversense Specialist Now
Call our priority access line at (877) 838-8003 between 8:00 AM and 7:00 PM ET
OR
We will call you within one business day. If we can't reach you, we will follow up by text and email.
Good news! Eversense 365 may be a match.
Next, you'll connect with a live Eversense Specialist. They can answer important questions, including about insurance coverage. There are 2 ways to connect:
Schedule a call with a live Eversense Specialist
Schedule a CallOR
We will call you within one business day. If we can't reach you, we will follow up by text and email.
Thanks! We've got your info.
Unfortunately, based on the information provided, you may not be eligible for an Eversense CGM at this time. If you have any questions, or believe this may be incorrect, please reach out to an Eversense Specialist at 1-844-736-7348.
To learn more about eligibility, click “Learn More” below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.